Company Research Report: Calla Lily Clinical Care Ltd

Company Overview

Name: Calla Lily Clinical Care Ltd.

Mission: Transforming drug delivery for women, particularly supporting fertility, pregnancy, a healthy vaginal microbiome, and other gynaecological conditions.

Founded: 2021

Founders: Dr. Lara Zibners and Thang Vo-Ta

Key People in the Company:

Dr. Lara Zibners - Co-founder & Chairman

Thang Vo-Ta - Co-founder & CEO

Prof. Andrew Lewis - Principal Scientist

Ewa Radziwon - Product Development Manager

Dr. Yasmin Farhatnia - R&D Manager

Akeel Khan - Chief Product Officer

Dr. Serena de Gelidi - Senior Biomechanical Engineer

Stuart Prince - Chief Financial Officer

Shaun Knights - Head of Regulatory & Quality

Headquarters: Charles House, 108-110 Finchley Road, London, NW3 5JJ, UK

Number of Employees: No information is available

Revenue of the Company: No information is available

Known For: Calla Lily Clinical Care is recognized for developing the Callavid® platform technology, a novel leak-free vaginal drug delivery system.

Products

Callavid® Technology

High-Level Description: Callavid® is a patented platform technology aimed at providing a leak-free, convenient, and dosage-confident experience for vaginal drug delivery. This technology is still under development and awaiting regulatory approval.

Key Features:

Leakage Protection: Incorporates an absorbent mini-liner to prevent leakage.

Placement & Dosage Confidence: Enhances secure placement and assurance of correct dosage.

Comfort and Convenience: Designed for ease of insertion and removal, reducing mess and discomfort.

Reduced Drug Absorption Variability: Provides reliable drug dosage absorption.

Sustainable Footprint: Developed with a focus on cost-effectiveness and environmental sustainability in manufacturing.

Recent Developments

Recent Developments: No specific new products have been launched, but Calla Lily Clinical Care continues to develop the Callavid® technology with ongoing research and receiving grant support from Innovate UK in 2022 and 2023.

Partnerships: Collaborates with leading biopharmaceutical companies and University Hospitals Coventry & Warwickshire for clinical trials of vaginal progesterone devices, led by Professor Siobhan Quenby.

Additional Information

Although Calla Lily Clinical Care Ltd is a relatively new entity, having been formed in 2021 from Callaly, it is emerging as a pioneer in women’s healthcare, particularly in reproductive health. Through their innovative Callavid® technology, they are addressing critical issues in vaginal drug delivery systems, offering benefits for conditions such as miscarriage and IVF treatments. Their ongoing research and strategic partnerships position them well to leverage new medical guidance and potentially expand market opportunities in women’s health globally.

Contact:

Email: info@callali.ly

Phone: +44 (0) 20 7754 5400